- Home
- IMCC vs MBIO Comparison
IMCC vs MBIO Comparison
Compare IMCC & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- MBIO
- Stock Information
- Founded
- IMCC 1980
- MBIO 2015
- Country
- IMCC Israel
- MBIO United States
- Employees
- IMCC N/A
- MBIO N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- MBIO Health Care
- Exchange
- IMCC Nasdaq
- MBIO Nasdaq
- Market Cap
- IMCC 7.5M
- MBIO 7.3M
- IPO Year
- IMCC N/A
- MBIO N/A
- Fundamental
- Price
- IMCC $1.58
- MBIO $1.44
- Analyst Decision
- IMCC
- MBIO Strong Buy
- Analyst Count
- IMCC 0
- MBIO 1
- Target Price
- IMCC N/A
- MBIO $100.00
- AVG Volume (30 Days)
- IMCC 8.3K
- MBIO 66.3K
- Earning Date
- IMCC 03-31-2025
- MBIO 05-14-2025
- Dividend Yield
- IMCC N/A
- MBIO N/A
- EPS Growth
- IMCC N/A
- MBIO N/A
- EPS
- IMCC N/A
- MBIO N/A
- Revenue
- IMCC $37,551,778.00
- MBIO N/A
- Revenue This Year
- IMCC $22.59
- MBIO N/A
- Revenue Next Year
- IMCC $32.86
- MBIO N/A
- P/E Ratio
- IMCC N/A
- MBIO N/A
- Revenue Growth
- IMCC 10.71
- MBIO N/A
- 52 Week Low
- IMCC $1.50
- MBIO $1.20
- 52 Week High
- IMCC $8.10
- MBIO $65.00
- Technical
- Relative Strength Index (RSI)
- IMCC 36.99
- MBIO 33.40
- Support Level
- IMCC $1.50
- MBIO $1.20
- Resistance Level
- IMCC $1.84
- MBIO $1.51
- Average True Range (ATR)
- IMCC 0.14
- MBIO 0.11
- MACD
- IMCC -0.01
- MBIO 0.11
- Stochastic Oscillator
- IMCC 16.33
- MBIO 77.42
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.